BioCentury | Dec 5, 2020
Translation in Brief
James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more
Penn, Regeneron on AAV-encoded REGN-COV2A James Wilson-led University of Pennsylvania team is developing a gene therapy form of casirivimab/imdevimab (REGN-COV2) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). The collaboration is based on the potential for a single, intranasal...